ESC RCC adds to the spectrum of renal neoplasms associated with alterations in TSC genes and mTOR pathway, which may have consequences for the selection of specific targeted treatments (such as mTOR inhibitors) [52,53]. The gene discussed is MTOR; the disease is Renal neoplasm.